Skip to main content
Fig. 2 | Genome Medicine

Fig. 2

From: Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma

Fig. 2

Somatic mutational landscape of the main cohort. TMZ sensitivity was determined based on in vitro TMZ screening. The single nucleic variants (SNV) including point mutations, short insertion/deletions, and copy number amplifications and deletions of selected GBM driver genes were included. Alteration frequencies are shown on the right side. When available, copy number alteration results were inferred from the methods in the following order; WES (highest priority), Gliomascan, and RNAseq. EGFRvIII was identified from RNA-seq data. Moderate: missense or inframe deletion; high: frameshift, stop gained, splice donor or splice acceptor; M, methylated; UM, unmethylated; N/A, not available; C, classical; P, proneural; M, mesenchymal; GS, Gliomascan; WES, whole exome sequencing

Back to article page